180 Life Sciences Corp.
ATNF
$1.80
-$0.02-1.10%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -38.81% | -11.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.95% | -3.93% | |||
| Operating Income | 58.95% | 3.93% | |||
| Income Before Tax | 90.23% | -242.67% | |||
| Income Tax Expenses | 99.81% | -- | |||
| Earnings from Continuing Operations | 88.05% | -178.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 88.05% | -178.95% | |||
| EBIT | 58.95% | 3.93% | |||
| EBITDA | 59.21% | 4.07% | |||
| EPS Basic | 91.97% | -83.51% | |||
| Normalized Basic EPS | 72.81% | 36.58% | |||
| EPS Diluted | 91.97% | -83.51% | |||
| Normalized Diluted EPS | 72.81% | 36.58% | |||
| Average Basic Shares Outstanding | 48.84% | 52.02% | |||
| Average Diluted Shares Outstanding | 48.84% | 52.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
